Navigation Links
James B. Hawkins Appointed to IRIDEX Board of Directors
Date:10/15/2007

hetics business acquired from Laserscope and to realize efficiencies and synergies relating thereto, and the results of the company's ongoing business, including order and shipment rates for the company's ophthalmology and dermatology product lines, the rate of sales to OEM customers, the rate of growth in sales of disposables and services, the rate of introduction and market acceptance of the company's products, and the impact of any continuing weakness and uncertainties related to general economic conditions or weakness in overall demand in the company's markets, especially with regard to the company's dermatology products which are typically used for elective procedures that can be deferred. Please see a detailed description of these risks and other risks that the company is subject to contained in our Quarterly Reports on Form 10-Q and Annual Report on Form 10-K for the fiscal year ended December 30, 2006 filed with the Securities and Exchange Commission. Forward- looking statements contained in this announcement are made as of this date and will not be updated.


'/>"/>
SOURCE IRIDEX Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Blair Offers James Support To Fight AIDS
2. James Cook University urges more medical seats
3. Wood Appointed As the First Chair of SAADAT
4. Yoga Guru appointed Bihars brand ambassador
5. Disappointed Students Plan To Intensify Agitation Nationwide
6. City Surgeon Appointed Adviser To Armed Forces
7. Indian-American Appointed for US Hospital Top Post
8. Retiring Government Doctors to Be Reappointed to Overcome Paucity of Specialists
9. Study casts doubt on keyboard ills
10. Who Board To Discuss Asian Tsunami Related Health Issues
11. Abdominal Crunches Not The Best Option For Wash Board Abs.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2008)...tiretroviral therapy may be due to genetic factors... A new study challenges the long-held belief that ...tem,s ability to restore itself after HIV patients...rapy (HAART). , From 50 percent to 90 percent o...CV. Intravenous drug use is the main cause of both...
(Date:7/25/2008)...ng overweight or obese is not only a personal issu...ealth issue that impacts other people in society. ...ch reveals that the extra Medicare cost associate...nificant financial burden on tax payers, costing u...tire current Medicare population. , The article...
(Date:7/25/2008)... consumers tips and encourages them to, ,Speak Up...., July 25 /PRNewswire-USNewswire/ -- The Pennsylv...onal Patient Safety Day" which,is a national effor...icipate fully in their healthcare by asking questi...urgery or illness., "We understand the important ...
(Date:7/25/2008)...the number of jobs created in the medical field sl...different kind of slowdown: they laid off fewer pe... Seattle, WA (PRWEB) July 25, 2008 -... field slowed in June overall, pharmaceutical comp...ill be music to the ears of sales representatives:...
Breaking Medicine News(10 mins):Health News:Study Disproves Belief That Hepatitis C Blunts HIV Drugs 2Health News:Patient Safety Authority Supports 'National Patient Safety Day' 2Health News:Patient Safety Authority Supports 'National Patient Safety Day' 3Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 2Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 3
...t first glance, it is difficult to believe anyone ... of Germans bathe in them every year to benefit th...tory as a natural cure. Patients have sought out ... in Brandenburg for more than a century, originall...
... trial of Aranesp an anemia drug from Amgen Inc di...dvanced cancer patients. This has reiterated the f...ricted conditions only. The mode of action of Ara...led erythropoietin (EPO) which augments the produc...
... first study, appearing in the February issue of R...to study the brains of a large group of babies// s...n and around the brains of one in four babies who ...ds in and around the brain are very common in infa...
...ird flu has come to Russia after quarantine measur...flu in 2006 resulted in an epidemic that called fo... outbreak is near the country’s Black Sea coast. ...vered the H5N1 bird flu virus in poultry at three ...
Other Medicine News:Health News:Germany's Therapeutic Mud Baths Have Healing Qualities 2Health News:Risk of Hemorrhage Increased in Vaginally Born Babies 2
(Date:7/24/2008)...W, Calif., July 24 /- Alexz... today that it has initiated,its second Phase 3 cl...Z-004 is an inhalation product candidate being dev...ients with schizophrenia or bipolar disorder.,Alex...id pharmacokinetic,(PK) properties resulting from ...
(Date:7/24/2008)...July 24 /PRNewswire-USNewswire/ -- Headlines claim...he whole story. The small scale,preliminary study...n,Reproduction, is based on recollected intake of ...oods. "This study is confounded by many,issues, th...t deal of,caution," warned Dr. Tammy Hedlund, a re...
(Date:7/24/2008)...y thermometer designed to take body temperature, f...-- Kidz-Med, Inc.,(subsidia...ts: ASFX),United States distributor of the Thermo...d to announce the results of a clinical study,cond...rsity of Milan, in,Milan, Italy, which proves that...
(Date:7/24/2008)...OLIS, France, July 24 /- Ni... top-line results from the 52-week,open label safe...letion of,the 301 phase 3 study for naproxcinod. T...and efficacy was maintained for the one-year durat...bal assessment scale. In,addition, the results sho...
Breaking Medicine Technology:Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 2Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 3Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 4Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 5Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 6Soyfoods Do Not Impact Sperm Count 2Pediatric Study Finds 21st Century Non-Contact Thermometer as Accurate as Conventional Thermometers 2NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 2NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 3NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 4Mylan Restores Availability of Generic Levothyroxine in Florida 11381 1Mylan Restores Availability of Generic Levothyroxine in Florida 11381 2Chindex International Inc Announces Results for the Quarter and Nine Months Ended December 31 2007 11378 1Chindex International Inc Announces Results for the Quarter and Nine Months Ended December 31 2007 11378 2Chindex International Inc Announces Results for the Quarter and Nine Months Ended December 31 2007 11378 3Chindex International Inc Announces Results for the Quarter and Nine Months Ended December 31 2007 11378 4Chindex International Inc Announces Results for the Quarter and Nine Months Ended December 31 2007 11378 5Chindex International Inc Announces Results for the Quarter and Nine Months Ended December 31 2007 11378 6Chindex International Inc Announces Results for the Quarter and Nine Months Ended December 31 2007 11378 7Chindex International Inc Announces Results for the Quarter and Nine Months Ended December 31 2007 11378 8Chindex International Inc Announces Results for the Quarter and Nine Months Ended December 31 2007 11378 9Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 1Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 2Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 3Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 4Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 5Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 6Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 7Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 8Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 9Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 10Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 11Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 12Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 13Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 14Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 15Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 16Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 17Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 18Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 19Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 20Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 21Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 22Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 23Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 24Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 25Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 26Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 27Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 28Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 29Roche Purchases Shares in Tender Offer for Ventana 11373 1Roche Purchases Shares in Tender Offer for Ventana 11373 2Roche Purchases Shares in Tender Offer for Ventana 11373 3Roche Purchases Shares in Tender Offer for Ventana 11373 4
... Breakthrough Will Aid in Developing Therapies to ... EMERYVILLE, Calif., May 10, 2007 /PRNewswire/ -- ...development company, announced,today the first met...issues in animals through the pathway known as rev...known mechanism by which excess,cholesterol can be...
...taly--(BUSINESS WIRE)--May 14, 2007 - Acceleron Ph... therapeutics for the,treatment of musculoskeletal...ounced results of a preclinical study with,ACE-031...increase,muscle mass and strength in normal mice a... inhibits negative regulators of muscle,to increas...
Other Medicine Technology:KineMed Presents Data Measuring Changes in Reverse Cholesterol,Transport for the First Time 2KineMed Presents Data Measuring Changes in Reverse Cholesterol,Transport for the First Time 3Acceleron Pharma's ACE-031 Increases Muscle Mass and Strength in,Preclinical Studies 2Acceleron Pharma's ACE-031 Increases Muscle Mass and Strength in,Preclinical Studies 3
For the measurement of vaginal pH as part of a self examination programme to help reduce the risk of pre-term birth
For the qualitative detection of human Chorionic Gonadotrophin (HCG) in urine or urine and serum specimens
ZyDoc offers a full medical transcription and documentation solution.
For the qualitative detection of single and multiple drugs and drug metabolites in human urine
Medicine Products: